文献速递治疗药物监测与药物基因组学

多基因评分在药物基因组学中应用的系统综述与分析

A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics.
PubMed 文献 · Clin Pharmacol Ther · 2022-01-17

该系统综述分析了51篇探讨多基因评分(PGS)用于药物相关结局的论文,多数聚焦精神疾病治疗(30篇)。研究多基于疾病表型的大规模全基因组关联研究推导PGS,参与者以欧洲血统为主(78.4%),方法学和报告存在显著异质性。

要点

  • PGS在药物基因组学中多用于精神疾病治疗结局预测
  • 多数PGS源自疾病表型GWAS而非药物反应GWAS
  • 研究参与者以欧洲血统为主,存在明显人群偏倚

核心结论

  • PGS在药物基因组学中应用前景广阔,但当前研究存在人群偏倚、方法异质性和报告不透明等缺口。

研究设计与样本

  • 系统综述与配套分析,纳入51篇探讨PGS用于药物相关结局的论文。

主要发现

  • 多数论文聚焦精神疾病治疗(30篇)。
  • 多数药物基因组学PGS源自与所研究药物基因组表型相关的疾病表型大规模GWAS。
  • 研究队列参与者以欧洲血统为主(78.4%)。
  • 研究机构集中于欧洲和北美,无来自非洲或南亚机构的第一或最后作者。

局限性

  • 难以收集大规模均匀治疗患者队列。
  • PGS分析及结果报告在风险模型开发与应用方面存在显著不一致。
  • 数据透明性和可及性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polygenic scores (PGSs) have emerged as promising tools for complex trait risk prediction. The application of these scores to pharmacogenomics provides new opportunities to improve the prediction of treatment outcomes. To gain insight into this area of research, we conducted a systematic review and accompanying analysis. This review uncovered 51 papers examining the use of PGSs for drug-related outcomes, with the majority of these papers focusing on the treatment of psychiatric disorders (n = 30). Due to difficulties in collecting large cohorts of uniformly treated patients, the majority of pharmacogenomic PGSs were derived from large-scale genome-wide association studies of disease phenotypes that were related to the pharmacogenomic phenotypes under investigation (e.g., schizophrenia-derived PGSs for antipsychotic response prediction). Examination of the research participants included in these studies revealed that the majority of cohort participants were of European descent (78.4%). These biases were also reflected in research affiliations, which were heavily weighted towards institutions located in Europe and North America, with no first or last authors originating from institutions in Africa or South Asia. There was also substantial variability in the methods used to develop PGSs, with between 3 and 6.6 million variants included in the PGSs. Finally, we observed significant inconsistencies in the reporting of PGS analyses and results, particularly in terms of risk model development and application, coupled with a lack of data transparency and availability, with only three pharmacogenomics PGSs deposited on the Polygenic Score Catalog. These findings highlight current gaps and key areas for future pharmacogenomic PGS research.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Johnson D, Wilke MAP, Lyle SM, et al. A Systematic Review and Analysis of the Use of Polygenic Scores in Pharmacogenomics. Clin Pharmacol Ther. 2022. PMID: 34953075. doi:10.1002/cpt.2520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。